The incidence of antithrombotic-associated gastrointestinal (GI) bleeding is increasing due to the growing advanced age population. There is consensus on ceasing anticoagulant and antiplatelet agents during an acute GI bleeding… Click to show full abstract
The incidence of antithrombotic-associated gastrointestinal (GI) bleeding is increasing due to the growing advanced age population. There is consensus on ceasing anticoagulant and antiplatelet agents during an acute GI bleeding episode but clearer guidance is needed on resumption of these agents. This article reviews evidence for optimal management of antithrombotics in the setting of acute GI bleeding and highlights areas in which future studies are needed.
               
Click one of the above tabs to view related content.